...
首页> 外文期刊>Leukemia >The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group
【24h】

The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group

机译:儿童肿瘤小组的报告:NOTCH1,FBW7和PTEN突变对小儿T细胞急性淋巴细胞白血病预后和下游信号的影响

获取原文
   

获取外文期刊封面封底 >>

       

摘要

We explored the impact of mutations in the NOTCH1, FBW7 and PTEN genes on prognosis and downstream signaling in a well-defined cohort of 47 patients with pediatric T-cell acute lymphoblastic leukemia (T-ALL). In T-ALL lymphoblasts, we identified high-frequency mutations in NOTCH1 (n=16), FBW7 (n=5) and PTEN (n=26). NOTCH1 mutations resulted in 1.3- to 3.3-fold increased transactivation of an HES1 reporter construct over wild-type NOTCH1; mutant FBW7 resulted in further augmentation of reporter gene activity. NOTCH1 and FBW7 mutations were accompanied by increased median transcripts for NOTCH1 target genes (HES1, DELTEX1 and cMYC). However, none of these mutations were associated with treatment outcome. Elevated HES1, DELTEX1 and cMYC transcripts were associated with significant increases in transcript levels of several chemotherapy relevant genes, including MDR1, ABCC5, reduced folate carrier, asparagine synthetase, thiopurine methyltransferase, BCL2 and dihydrofolate reductase. PTEN transcripts positively correlated with HES1 and cMYC transcript levels. Our results suggest that (1) multiple factors should be considered with attempting to identify molecular-based prognostic factors for pediatric T-ALL, and (2) depending on the NOTCH1 signaling status, modifications in the types or dosing of standard chemotherapy drugs for T-ALL, or combinations of agents capable of targeting NOTCH1, AKT and/or mTOR with standard chemotherapy agents may be warranted.
机译:我们在47例小儿T细胞急性淋巴细胞性白血病(T-ALL)患者的明确队列中探讨了NOTCH1,FBW7和PTEN基因突变对预后和下游信号的影响。在T-ALL淋巴母细胞中,我们在NOTCH1(n = 16),FBW7(n = 5)和PTEN(n = 26)中发现了高频突变。与野生型NOTCH1相比,NOTCH1突变导致HES1报告基因构建体的反式激活增加了1.3到3.3倍;突变体FBW7导致报告基因活性进一步增强。 NOTCH1和FBW7突变伴随着NOTCH1目标基因(HES1,DELTEX1和cMYC)的中位转录本增加。但是,这些突变均与治疗结果无关。升高的HES1,DELTEX1和cMYC转录物与几种与化疗相关的基因,包括MDR1,ABCC5,还原叶酸载体,天冬酰胺合成酶,硫代嘌呤甲基转移酶,BCL2和二氢叶酸还原酶的转录水平显着增加有关。 PTEN成绩单与HES1和cMYC成绩单呈正相关。我们的结果表明(1)在尝试确定基于分子的小儿T-ALL预后因素时应考虑多种因素,并且(2)取决于NOTCH1信号状态,标准化疗药物的类型或剂量的改变-ALL或能够靶向NOTCH1,AKT和/或mTOR的药物与标准化疗药物的组合可能有保证。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号